NICE recommends Selincro for alcohol dependence

The U.K.'s NICE issued final guidance recommending the use of Selincro nalmefene from H. Lundbeck A/S (CSE:LUN) to reduce alcohol consumption by adults with alcohol dependence who have a high drinking risk level without physical withdrawal symptoms and who do not require immediate detoxification. The European Commission approved Selincro to reduce alcohol consuption in adults with alcohol dependence last year (see BioCentury Extra, Feb. 28, 2013).

NICE recommends that Selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Its recommendation is in line with draft guidance issued in July (see BioCentury Extra, July 9). ...